Pltr Stock Discussion: Palantir Technologies Stock Analysis and Investment Strategies

Palantir Technologies, the company behind PLTR stock, was founded in 2003 by Peter Thiel, a well-known entrepreneur and investor.

Palantir's early success was largely driven by its work with the US government, particularly the CIA and the NSA.

The company's software, known as Gotham, was used to analyze and visualize large datasets, providing valuable insights for national security purposes.

This work helped establish Palantir as a leader in the field of data analytics and visualization.

Suggestion: Tobacco Company Stock Code

Palantir's stock performance has been quite volatile, with some significant price movements in recent times.

The stock price has been a favorite among speculative investors, with lots of interest around the PLTR stock price today and its latest volatile moves.

Investors are keenly analyzing the impact of Palantir's new contract with the NHS on the company's financial health and stock performance.

This contract, worth up to £480 million, has led to a 20% pop in shares after Palantir's third-quarter results beat estimates.

Palantir's stock has also seen a significant gain of 4.5x since the beginning of the year, trading at about $82 per share currently.

However, the stock slipped 4.22% on Friday, followed by a 1.8% slide in pre-market trading Monday, as investors cashed in gains amid profit-taking.

Related reading: Brk Class B Stock Fund

Palantir Technologies Inc. PLTR dipped 4.22% on Friday, followed by a 1.8% slide in pre-market trading Monday, as investors cashed in gains amid a blistering 2024 run.

This profit-taking has led to a temporary slip in the stock's value, but it's essential to consider the bigger picture. Palantir's stock has delivered a remarkable 395% return this year, outperforming the entire S&P 500.

The stock has also risen over 4.5x since the beginning of the year, trading at about $82 per share currently. This significant growth is a testament to the company's strong performance.

However, concerns are growing about the stock's lofty valuation, which may be a reason for the recent profit-taking.

Discover more: How Many Stocks Are in Brk B

Members of Congress have traded Palantir Technologies stock 13 times in the past 6 months, with 10 purchases and 3 sales.

The majority of these trades were sales, with 3 out of the 13 trades being purchases.

Palantir Technologies insiders have traded stock on the open market 266 times in the past 6 months, with 1 purchase and 265 sales.

Here's a breakdown of the recent trading activity by Palantir Technologies insiders:

Nvidia's valuation has grown significantly, with the company rising 240% last year and becoming the top performer in the S&P 500 index.

This impressive performance is a testament to Nvidia's strong position in the A.I. trade.

Broaden your view: Nvidia Corporation 5-10 Year Stock

Tom White, a well-known expert, has identified some unusual bullish trades in A.I. companies, including PLTR stock.

PLTR is a company that has been making waves in the A.I. industry.

In today's market, investors are looking for opportunities to grow their portfolios, and PLTR stock is one of the options being considered.

According to Tom White, PLTR has potential for growth, making it a good choice for investors looking to invest in A.I. companies.

Curious to learn more? Check out: Snp 500 Companies

As a retail investor, it's essential to consider the impact of Palantir's contract with the NHS on its financial performance. This contract signifies Palantir's growing influence in the global data analytics market.

Palantir's expansion into healthcare data analytics represents a diversification from its traditional focus on government and defense contracts. This diversification can reduce the risk profile for investors, making Palantir a more stable investment with potential for growth in new markets.

Palantir's capabilities in advanced technology and AI are rapidly growing and evolving, making it an attractive investment for retail investors interested in these areas. The company's demonstrated expertise and ongoing development in these areas are significant advantages.

However, retail investors need to consider the controversy and ethical concerns surrounding Palantir's NHS contract. These concerns can impact investor sentiment and the company's reputation, which can influence stock performance.

Here are some key points to consider for retail investors:

Palantir's ability to forge significant global partnerships, such as its collaboration with the NHS and Accenture, suggests its potential for further international expansion. This can open up new markets and opportunities for revenue growth, making Palantir an attractive investment for long-term investors.

For more insights, see: Ford Class B Stock

Apple's 2024 rally has been impressive, with the stock up over a certain percentage on the year. This makes it an attractive option for traders looking to capitalize on its momentum.

One option to consider is buying calls on AAPL, which could potentially yield significant gains if the stock continues to rise.

The explosive rally of Palantir, another stock mentioned in the article, highlights the potential for stocks to make big moves to the upside.

Palantir Technologies is delivering value across various industries, including supply chains and production processes.

The company's success has led to it being one of the best-performing tech stocks in the S&P 500 in 2024, alongside Nvidia and Broadcom.

Palantir, Nvidia, and Broadcom are forecasted to be the top-performing tech stocks in 2025, according to industry experts.

These tech stocks have shown remarkable growth and are expected to continue their upward trend in the coming year.

Palantir's expansion into healthcare data analytics suggests potential growth for investors. The company's contract with the NHS signifies its growing influence in the global data analytics market, which may positively impact Palantir's financial performance and stock value.

For retail investors, Palantir's diversification from traditional government and defense contracts reduces risk and offers a stable investment opportunity. This diversification can lead to potential growth in new markets.

Palantir's technological innovation and AI development capabilities make it an attractive investment for those interested in AI and tech innovation. The company's demonstrated expertise and ongoing development in these areas can drive long-term growth.

Growth investors may find Palantir stock appealing due to its expansion into new markets and sectors, indicating potential for increased revenue and market share.

Palantir Technologies has received a significant amount of attention from analysts, with 14 of them issuing price targets for the company in the last 6 months.

The median target price set by these analysts is $162.5, which indicates a general optimism about the company's future performance.

Gabriela Borges from Goldman Sachs set a target price of $141.0 on August 6, 2025, suggesting a more cautious approach to Palantir's growth prospects.

Gil Luria from DA Davidson, on the other hand, is more bullish, setting a target price of $170.0 on August 5, 2025.

Thomas Blakey from Cantor Fitzgerald and Mariana Perez Mora from B of A Securities also set high target prices of $155.0 and $180.0, respectively, on August 5, 2025.

Here are the recent price targets set by analysts for Palantir Technologies:

As you're considering Palantir Technologies for your investment portfolio, it's essential to take a closer look at the analyst ratings.

Analysts have been weighing in on Palantir, with 4 firms issuing buy ratings and 2 firms issuing sell ratings. This mixed bag of opinions can be a good or bad sign, depending on your investment strategy.

The analyst ratings for Palantir are as follows:

Considering these ratings, you may want to weigh the pros and cons of investing in Palantir Technologies.

Growth investing focuses on stocks of companies expected to grow at an above-average rate compared to other stocks in the market. This can be a great way to grow your wealth over time.

Palantir's expansion into healthcare data analytics and its contract with the NHS suggest potential growth. Investors interested in growth stocks might see Palantir stock as an appealing option due to its expansion into new markets and sectors.

The company's diversification into healthcare data analytics marks a significant shift from its traditional focus on government and defense contracts. This diversification can reduce the risk profile for investors, as the company is not solely dependent on one sector for its revenue.

Palantir's collaboration with the NHS and partners like Accenture indicates the company's ability to forge significant global partnerships. For retail investors, this suggests Palantir's potential for further international expansion, opening up new markets and opportunities for revenue growth.

For another approach, see: How Are Stock Speculators Different from Stock Investors

Palantir's growing influence in the global data analytics market, as seen in its contract with the NHS, can positively impact the company's financial performance and stock value. This makes it an attractive option for growth investors.

Here are some key factors to consider when evaluating Palantir as a growth investment:

These factors can help you determine whether Palantir is a good fit for your growth investing strategy.

Analysts are bearish on PLTR stock, with 15 analysts giving it an average rating of "Hold" and a 12-month stock price forecast of $39.92, which is a decrease of -50.03% from the latest price.

Some analysts are more optimistic, with Dan Ives of Wedbush Securities predicting that PLTR shares may be the next Salesforce or Oracle, given their impressive 350% gain in 2024.

Palantir's recent performance has been strong, with shares popping 20% after its third-quarter results beat estimates, according to CNBC.

Industry experts like Alex Fishman of Empros Capital believe that Palantir needs to be the "glue" for AI and defense, highlighting the company's potential in these areas.

The UK's NHS has also shown its faith in Palantir, handing the company a lucrative contract worth up to £480 million for patient data software, as reported by Bloomberg and Reuters.

Palantir Technologies Inc. has a significant contract with the National Health Service (NHS) in the UK, potentially valued at £480 million.

The contract involves collaborating with Accenture Plc. and aims to enhance medical data analysis, resource allocation, and improve patient discharge processes.

Palantir's shares dipped post-announcement but are rising once more today, reflecting investor apprehension.

The company has diversified from its initial focus on government contracts to offering business intelligence solutions.

Palantir is known for its AI platforms initially designed for counterterrorism.

The contract is extendable beyond five years and will implement a federated data platform with safeguards like a privacy-enhancing tool from Iqvia Holdings Inc.

Palantir has faced controversies, particularly around its NHS work, with debates over data transparency, usage, and patient opt-out options.

The company has a market value and technological advancements, especially in AI, that position it as a notable player in the tech and health data sectors.

Worth a look: Deep Seek Ai Stock

Palantir's stock has been a favorite among speculative investors, with lots of interest around the PLTR stock price today and its latest volatile moves.

Members of Congress have traded $PLTR stock 13 times in the past 6 months, with 10 purchases and 3 sales. This has led to a mix of optimism and caution in PLTR stock discussions, reflecting diverse investor sentiments.

Some investors are bullish about the potential growth from Palantir's new contract with the NHS, while others express concerns over data privacy controversies and their impact on the company's reputation and stock value.

The PLTR stock conversation extends beyond financial metrics, delving into the company's ethical practices and governance, factors increasingly important to socially conscious investors. These discussions reflect a holistic view of the company, considering both its financial prowess and its societal impact.

Here are some of the largest recent moves in institutional investor activity:

The real-time quote for Pltr stock is -$7.48, a decrease of 4.12% from its previous value. This is based on a short-term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months.

The Zacks Rank system is a key part of this rating system, with rankings ranging from 1 (Strong Buy) to 5 (Strong Sell). The system also includes a VGM Score, which combines the weighted average of the individual style scores into one score.

Here's a breakdown of the Zacks Rank system:

The scores are based on the trading styles of Value, Growth, and Momentum. The VGM Score is a weighted average of these individual style scores, with a higher score indicating a better performance.

The industry with the best average Zacks Rank would be considered the top industry, which would place it in the top 1% of Zacks Ranked Industries.

Suggestion: Crwd Zacks Rating

Palantir stock has seen an incredible 4.5x gain this year, with its price trading at about $82 per share. This remarkable growth has many investors wondering if it's time to rethink their strategy.

The stock's performance has been driven by significant deals, such as the £480 million NHS contract, which has sparked optimism about the company's potential for growth. However, concerns about data privacy controversies and their impact on the company's reputation are also being discussed.

Check this out: Compared to Growth Stocks Value Stocks' Price-earnings Ratio Is Typically

Palantir's market capitalization and technological innovations are also being analyzed, with investors considering both the company's financial prowess and its societal impact. The stock's conversation extends beyond financial metrics, delving into the company's ethical practices and governance.

The stock's volatility has been evident in recent moves, with a 4.22% dip on Friday and a 1.8% slide in pre-market trading Monday, as investors cashed in gains amid profit-taking. Despite this, the stock has still delivered a remarkable 395% return this year, outperforming the entire S&P 500.

A different take: Ameriprise Financial Stock Price History

Palantir Technologies has seen significant hedge fund activity in recent quarters. A total of 1,631 institutional investors added shares of Palantir stock to their portfolio, while 932 decreased their positions.

One of the largest recent moves was made by KINGSTONE CAPITAL PARTNERS TEXAS, LLC, which added 18,661,152 shares to their portfolio in Q2 2025, valued at an estimated $2,543,888,240.

BLACKROCK, INC. removed 11,014,628 shares from their portfolio in Q2 2025, a decrease of 5.9% and valued at an estimated $1,501,514,088. JPMORGAN CHASE & CO also removed 7,716,375 shares, a 32.4% decrease and valued at an estimated $1,051,896,240.

For your interest: Nflx Stock Forecast 2025

On the other hand, VANGUARD GROUP INC added 7,194,216 shares to their portfolio in Q2 2025, a 3.6% increase and valued at an estimated $980,715,525. NORGES BANK added 6,277,645 shares, a 34.9% increase and valued at an estimated $855,768,566.

Other notable moves include STATE STREET CORP adding 6,097,629 shares, a 6.9% increase and valued at an estimated $831,228,785, and GEODE CAPITAL MANAGEMENT, LLC removing 5,723,603 shares, a 10.3% decrease and valued at an estimated $780,241,560.

Here is a summary of the largest recent moves:

Palantir Technologies has been making headlines lately. Morgan Stanley assigned a new analyst to cover the company, which is a significant development in the world of Palantir stock.

Investors are closely watching the company's financial health and stock performance, particularly after its new contract with the NHS. This deal has sparked a mix of optimism and caution on Palantir's stock message boards.

Palantir's market capitalization, technological innovations, and ability to secure high-profile contracts are all being closely scrutinized. The company's ethical practices and governance are also being considered by socially conscious investors.

Salesforce CEO Marc Benioff has expressed admiration for Palantir, which is a notable endorsement. However, Morgan Stanley's new analyst is forecasting worse times ahead for the stock.

Additional reading: Nvda Morgan Stanley Targewt Price

Congressional Stock Trading is a topic that's been making headlines lately. Members of Congress have traded $PLTR stock 13 times in the past 6 months.

Of those trades, 10 have been purchases and 3 have been sales.